This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CryoLife's CEO Discusses Acquisition Of Hemosphere, Inc. Conference (Transcript)

CryoLife, Inc. (CRY)

Acquisition of Hemosphere, Inc by CryoLife, Inc. Call

May 15, 2012 11:00 am ET


Steven G. Anderson – Chairman, President and Chief Executive Officer

D. Ashley Lee – Executive Vice President, Chief Operating Officer, Chief Financial Officer and Treasurer


Jeffrey S. Cohen – Ladenburg Thalmann & Co.

Matt Dolan – Roth Capital Partners

Raymond Myers – The Benchmark Company, LLC



Greetings and welcome to the CryoLife Update Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Steve Anderson, President and CEO for CryoLife. Thank you, Mr. Anderson, you may begin.

Steven G. Anderson

Good morning, everyone, and welcome to CryoLife’s Hemosphere acquisition conference call. This is Steven Anderson, CryoLife’s President and CEO. I’m joined today by Ashley Lee, CryoLife’s Executive Vice President, COO and CFO. We’d like to thank you for joining us on this call to discuss the acquisition of Hemosphere that we announced earlier this morning.

Before going farther, I want to remind everyone that we posted a slide presentation to accompany this conference call in the Investor Relations section of our corporate website at If you have not done so already, I encourage you to download these slides now.

The agenda for today’s call is as follows. I will open the call with some comments about the acquisition of Hemosphere and its strategic fit with CryoLife and the acquisition strategy that we have been working on for some time. Ashley will follow these comments with a detailed overview of the HeRO Graft business, the incremental opportunity it opens for CryoLife and the financial details of the transaction. After Ashley’s comments, we will open the call for questions.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs